For research use only. Not for therapeutic Use.
Sibeprenlimab（Cat No.:I042076）is an investigational monoclonal antibody designed to target and inhibit the PD-1 (programmed cell death protein 1) receptor. By blocking PD-1, it aims to enhance the body’s immune response, particularly in cancer treatment, where tumors often evade detection by the immune system. It is being studied in clinical trials for various cancers, including non-small cell lung cancer and other solid tumors. Its mechanism may lead to improved anti-tumor immunity, potentially offering a new therapeutic option for patients with resistant or advanced cancers.
| Catalog Number | I042076 |
| CAS Number | 2382896-07-1 |
| Purity | ≥95% |
